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A 66-year-old man had bilateral total hip arthroplasties 
for degenerative arthropathy in 1995. Following both 
interventions no complications were observed and he 
remained asymptomatic. Sedimentation and level of 
C-reactive protein (CRP) were within the normal 
range. His medical history was sigmficant for chronic 
obstructive pulmonary disease (COPD), arterial hyper- 
tension and hyperglycemia. 
On 23 December 1998 he was admitted to the 
hospital with a 3-day history of fever and coughing, and 
a 2-day history of a painful lefi hip with inability to bear 
weight. On  examination, the patient appeared ill with 
fever (38OC). Crepitations over his chest and painful 
bilateral lymph nodes in the cervical and supraclavicular 
regions were noted. The lefi hip was tender on pal- 
pation, and movement was painful. The white blood 
cell count was 23400/mm3 with a marked left shift, 
sedlmentation was 100 mm/h and the CRP 428 mg/L. 
A chest radiograph showed pneumonia. of the right 
upper lobe. Echography of the left hip showed an 
e&sion compatible with infection. 
Arthrocentesis of the lefi hip produced a purulent 
fluid, which on Gram stain revealed no bacteria, but on 
cultures grew a peniciUm-susceptible strain of Strepto- 
coccus pneumoniae, which w a s  found to be of serotype 
14. One set of blood cultures, taken at the same time 
revealed no growth. 
Antimicrobial therapy with intravenously admini- 
stered flucloxacilltn (6 g/day) and gentamicin (320 
mg/day) was started. O n  the fourth day of hospitali- 
zation, the patient developed a pain over his right hip 
with impaired mobility. Three mdlihters of purulent 
fluid was aspirated, but microscopy was not contri- 
butory and cultures revealed no growth. On  the 
fifth day, gentamicin was stopped because the patient 
developed progressive renal dyshnction (urea 240 
mg/dL, creatinine 4.9 mg/dL), and flucloxacillin was 
changed to intravenously administered ampicillin 
(6 glday). On the eighth day, surgical debridement of 
both hips was undertaken and, on both sides, massive 
amounts of brown purulent fluid were evacuated. 
Cultures taken at this time remained sterile. Joint pain 
subsequently resolved and both wounds healed un- 
eventfllly. Renal function improved. O n  day 14 of 
hospidzation, the patient was put on oral ampicillin 
(4 glday). Six weeks after admission, the patient was 
discharged &om hospital. At that time, CRP was 
decreased to 44.6 mg/L. The patient was asymptomatic 
and had regained good function of both hip joints. 
Treatment with oral ampicillin had to be continued for 
at least 6 months after the onset of infection. 
Pneumococci are Gram-positive diplococci. An 
important feature of t h s  pathogen is the possession of 
an extracellular polysaccharide capsule; to date, 90 
antigenically distinct types of capsule have been 
described [l]. In the laboratory, type-specific antisera 
are used to identlfy the merent types. The capsule is 
known to be an important virulence factor, as it 
interferes with phagocytosis and consequently favors 
invasiveness. Other virulence factors, recently described, 
are various intracellular and surface proteins (e.g. 
pneumolysin, neuraminidase, PspA, autolysin, hyaluro- 
nidase, IgA protease) [l-31. 
S. pneumoniae is the most important pathogen in 
community-acquired pneumonia, bacterial meningitis, 
otitis and sinusitis. Pneumonia is, in 15-25% of 
the cases, associated with positive blood cultures. The 
incidence of pneumococcal bacteremia in North 
America and Europe, as reported by Kalin [l] , is at least 
10-20/ 100 000 individuals. 
Pneumococcal infection of prostheses must be 
encountered Sequently, as it is never mentioned in 
review articles concerning S. pneumoniae. 
Prosthetic infection is one of the major problems 
in total joint arthroplasty. The incidence in recent years 
is estimated to be around l%, depending on several 
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factors such as surgical procedures (prophylactic use of 
antibiotics, sterility conditions in the operating room), 
type of prosthesis implanted and patient selection 
[4,5]. A prosthetic infection can be placed into one 
of three categories on the basis of pathogenesis and 
chronology: acute contiguous, chronic contiguous and 
hematogenous. 
The contiguous infections are caused by con- 
tamination of the prosthesis at the time of surgery. This 
can result either in an acute infection or a chronic, 
indolent, low-grade infection. Often these are caused 
by coagulase-negative staphylococci or other com- 
ponents of the normal skin flora. The other possible 
pathogenesis is hematogenous spread fkm a distant 
focus. These infections occur at any time after surgery 
and are characterized by an acute onset of symptoms. 
In a review of the literature, we found only seven 
other cases of prosthetic infection with pneumococci. 
Of those, four concerned infections of a hip prosthesis, 
two of a knee prosthesis and one of a hip and bilateral 
knee prosthesis. In our case, the infection affected both 
hip prostheses. The histories of the seven previously 
described cases and our case are summarized in Table 
1. Six of the eight patients were females and they all 
were over the age of 65 years. The latter is not 
surprising, since degenerative joint disease, resulting in 
the need for arthroplasty, is mostly encountered in the 
elderly. Also, it has generally been accepted that people 
of advanced age are more at risk for contracting a 
pneumococcal infection. 
Pneumococcal pneumonia has also been noted to 
occur with increased frequency in patients with a 
variety of underlying conditions such as congestive 
heart fdure, diabetes, alcoholism and COPD. 
In the case reports presented here, one patient 
had diabetes, one received chemotherapy for breast 
cancer, and in one a stomach cancer was detected on 
admission. Our patient was known to have COPD and 
hyperglycemia. 
In this context, it is of interest to note that 
prostheses, like all implanted biomaterials, locally 
increase the susceptibility to every bacterial infection. 
Diminished host defense around foreign, avid material 
and facilitated bacterial adherence to the surface of 
biomaterials are the main mechanisms described [13- 
1 51. It is not certain, however, to what extent the latter 
mechanism also accounts for pneumococci, as research 
concerning this aspect is focused on staphylococci. 
In the reported cases, the presumed pathogenesis is 
hematogenous spread. First, all were late infections 
preceded by a completely asymptomatic period ranging 
fhm 13 months to 15 years after surgery. Second, they 
had an acute onset and/or a preceding infection at a 
focus remote fbm the prosthetic joint. Five patients 
had a pneumonia several days to 1 month More the 
diagnosis of infection of the prosthetic joint(s). In two 
of them sputum cultures were positive for pneumo- 
cocci, two patients had positive blood cultures for 
pneumococci, while in our patient no pneumococci 
could be isolated fi-om blood culture. In one patient, 
the diagnosis of a primary pneumococcal bacteremia 
was made. In two patients, no primary site of infection 
could be detected. 
In seven of the eight reported cases, the infection 
was characterized by an acute onset. In one patient a 
pneumonia with pneumococcal bacteremia was followed 
by an 8-month period of indolent prosthetic infection 
with few moderate exacerbations before clear clinical 
signs of infection occurred. This shows that pneumo- 
coccal infection of prostheses can have a more chronic 
The clinical presentation was similar in all cases: 
pain, erythema and swelling over the infected joint 
together with fever were the predominant symptoms. 
Laboratory findmgs, when mentioned, were con- 
sistent with bacterial infection (increased sedimentation 
and leukocytosis) . 
Management of prosthetic infection involves ad- 
ministration of antibiotics and adequate surgical inter- 
vention. 
Surgical treatment options include total debride- 
ment, extraction without replacement and one- or 
two-stage replacement. The recommended procedure 
depends on Merent factors such as patient charac- 
teristics (health, age), degree of prosthesis damage and 
the possibility of eradicating the infecting organism by 
antibiotic therapy. Pneumococci are not known to be 
slime producers and have, in general, good antibiotic 
susceptibility. Therefore, treatment of pneumococcal 
infection without prosthesis extraction is in most cases 
successful. This is documented by the case reports: eight 
of the 11 infected prostheses (in eight patients) could 
be saved. In one patient, extraction was done because 
symptoms of infection persisted despite debridement, 
and in another patient, loosening of the hip prosthesis 
was the reason for replacement. One patient who had 
underlying malignant disease developed septicemia 
following prosthetic infection and died 2 months after 
the onset of infection. 
Penicillin is the first-choice antibiotic for treatment 
of pneumococcal infections, though increasing resist- 
ance to penicillin is emerging. This mistance is due to 
altered penicillin-binding proteins which have decreased 
a%inity for $-lactam antibiotics. The percentage of 
penicillin-resistant pneumococci varies significantly, 
depending on the country. The Belgian National 
Reference Center for S. pneumoniue reports a rate 
of 14% for 1998. Therefore, for invasive infections, 
history. 
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susceptibility testing of the infecting organism should 
be done. In only one of the previously described cases 
was it mentioned that the pneumococcus was suscep- 
tible to penicillin. In five of the other cases, treatment 
with penicillin was successll. In one case, the patient 
died despite penicillin administration, but, as already 
mentioned above, she had a poor prognosis because of 
underlying malignant disease. In our patient, it con- 
cerned a penicillin-susceptible strain.  
The duration of antibiotic treatment depends on 
the evolution of the infection, which is evaluated by 
considering clinical symptoms, wound healing and 
levels of CRP and sedimentation. Parented admini- 
stration is prescribed until the infection is controlled, 
and then antibiotics are continued orally. When 
mentioned in the case reports, penicillin was given at a 
dose of 12-20 million units a day for 1-6 weeks, 
followed by oral penicillin for 1-3 months. Two 
patients were put on continuous suppressive anti- 
microbial therapy with penicillin. In our patient, 
empirical treatment with intravenous flucloxacillin 
(6 g/day) and gentamicin (320 mglday) was started. 
This regimen was changed to intravenous ampicillin 
(6 g/day) when the causative organism was identified. 
After 8 days of intravenous therapy, the patient was 
maintained on oral ampicillin (4 glday), which should 
be continued for at least 6 months after the onset of 
infection. 
In one case report, it was mentioned that the 
patient never received pneumococcd vaccination. In 
the other six case reports, t h i s  w a s  not stated. Our 
patient was not vaccinated. 
Current antipneumococcal vaccines comprise a 
mixture of 23 capsular polysaccharides h m  the most 
frequently encountered pneumococcal serotypes. At 
the present time, vaccination in Belgium is recom- 
mended for those aged 60 years and older. No 06cial 
recommendations exist to vaccinate patients who have 
prosthetic joints. It is, however, worth considering the 
need for vaccination in those patients. 
As discussed above, most of them already belong to 
the high-risk group for pneumococcal invasive in- 
fection. On the other hand, pneumococcus is not a 
likely cause of prosthetic joint infection. Furthermore, 
the prognosis of pneumococcal infection of prosthesis 
appears to be good, as illustrated by the reviewed cases. 
But even then, vaccination may be justified because of 
the high costs associated with treatment of prosthesis 
infection: long-term hospitalization and antibiotic 
administration, together with one or more surgical 
interventions. 
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